Mark Newman | Chief Scientific Officer
GeoVax

  Mark Newman, PhD, has 35 years’ experience in the biotechnology sector serving in senior management roles at GeoVax (Atlanta, GA), PaxVax (San Diego, CA), Pharmexa (Horsholm, Denmark), Epimmune (San Diego, CA), Vaxcel (Atlanta, GA), Apollon (Philadelphia, PA) and Cambridge Biotech (Boston, MA) where he directed research, development and early-stage clinical testing of protein, peptide, plasmid DNA and viral vectored vaccines and multiple vaccine adjuvants. He participated with or directed teams responsible for the transition of 10 vaccine or vaccine-related products from the research stage to Phase 1 and 2 clinical testing.  He also served as the primary scientific director for multiple corporate teams supporting due diligence, technology assessments, intellectual property review and portfolio management to support strategic planning, technology in-licensing and out-licensing, corporate partnering and mergers and acquisitions. Dr. Newman has authored or co-authored approximately 120 peer-reviewed scientific papers, reviews and book chapters during his professional career.  He is a named co-inventor on more than a dozen multiple issued US and PCT patents, all related to vaccine technologies.  He served as the Principal Investigator or Co-Investigator on numerous USA government research grants and contracts and works as a technology expert to support review of grants and contracts for the National Institutes of Health. Dr. Newman is a honors graduate of the Ohio State University (B.Sc. and M.Sc.) where he studied biology and animal science in a pre-veterinary medicine focused curriculum. He received his PhD in Immunology from the John Curtin School of Medical Research, the Australian National University (Canberra, Australia).  He completed four years post-doctoral training at Cornell University and the Uniformed Services University of Health Sciences under contract with the National Cancer Institute, National Institutes of Health.  He also served four years as a full-time member of the Louisiana State University faculty at the School of Veterinary Medicine prior to joining the biotechnology industry in 1989.